PE20060504A1 - Derivados de pirimidina en el tratamiento de cancer - Google Patents

Derivados de pirimidina en el tratamiento de cancer

Info

Publication number
PE20060504A1
PE20060504A1 PE2005000980A PE2005000980A PE20060504A1 PE 20060504 A1 PE20060504 A1 PE 20060504A1 PE 2005000980 A PE2005000980 A PE 2005000980A PE 2005000980 A PE2005000980 A PE 2005000980A PE 20060504 A1 PE20060504 A1 PE 20060504A1
Authority
PE
Peru
Prior art keywords
kinase
methyl
substituted
cancer
treatment
Prior art date
Application number
PE2005000980A
Other languages
English (en)
Inventor
Eiji Kawahara
Takahiro Miyake
Johannes Rosel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060504A1 publication Critical patent/PE20060504A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R0 ES H, R1 ES MONOCICLO SUSTITUIDO DE 6 ELEMENTOS O BICICLO-HETEROCICLO DE 10 ELEMENTOS CON 1-2 HETEROATOMOS DE N, O; R2 Y R3 JUNTO AL C Y N AL QUE ESTA UNIDO, FORMA UN HETEROCICLO QUE CONTIENE UN HETEROATOMO SELECCIONADO DE N, SUSTITUIDO O NO; R4 ES H; R5 ES HALOGENO; R6 Y R7 SON H; R8 ES H, ALCOXI C1-C7, CARBAMOILO SUSTITUIDO O NO POR ALQUILO C1-C7, ENTRE OTROS; R9 ES H; R10 ES H, HALOGENO, ALCOXI C1-C7. SON COMPUESTOS PREFERIDOS: 7-[5-CLORO-2-(2-METOXI-FENILAMINO)PIRIMIDI-4-NILAMINO]-2-METIL-4-PIPERAZI-1-NIL-2,3DIHIDRO-ISOINDO-1-LONA; 7-[5-CLORO-2-(2-METOXI-FENILAMINO)-PIRIMIDI-4-NILAMINO]-2-METIL-4-(4-METIL-PIPERAZI-1-NIL)-2,3-DIHIDRO-ISOINDO-1-LONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FERMACEUTICA Y A UN METODO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE CINASA NPM-ALK (ACTIVDAD TIROSIN-CINASA PROTEICA DEL LIGANDO INDEPENDIENTE DEL LINFOMA CINASA ANAPLASICA) UTILES EN EL TRATAMIENTO DE TUMOR DE PECHO, CANCER INTESTINAL, CANCER ESTOMACAL, MELANOMA, TUMOR DE VEJIGA, ENTRE OTROS
PE2005000980A 2004-08-27 2005-08-25 Derivados de pirimidina en el tratamiento de cancer PE20060504A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0419160.7A GB0419160D0 (en) 2004-08-27 2004-08-27 Organic compounds

Publications (1)

Publication Number Publication Date
PE20060504A1 true PE20060504A1 (es) 2006-07-18

Family

ID=33104745

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000980A PE20060504A1 (es) 2004-08-27 2005-08-25 Derivados de pirimidina en el tratamiento de cancer

Country Status (24)

Country Link
US (1) US7910585B2 (es)
EP (1) EP1784399B1 (es)
JP (1) JP4674236B2 (es)
KR (1) KR100894349B1 (es)
CN (1) CN101006079A (es)
AR (1) AR050536A1 (es)
AT (1) ATE512960T1 (es)
AU (1) AU2005276585B2 (es)
BR (1) BRPI0514731A (es)
CA (1) CA2575720C (es)
EC (1) ECSP077259A (es)
ES (1) ES2366038T3 (es)
GB (1) GB0419160D0 (es)
GT (1) GT200500229A (es)
IL (1) IL181386A0 (es)
MA (1) MA28813B1 (es)
NO (1) NO20071504L (es)
PE (1) PE20060504A1 (es)
PL (1) PL1784399T3 (es)
PT (1) PT1784399E (es)
RU (1) RU2395507C2 (es)
TN (1) TNSN07074A1 (es)
TW (1) TW200621728A (es)
WO (1) WO2006021457A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP2447360A1 (en) 2006-04-14 2012-05-02 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
TWI432427B (zh) 2006-10-23 2014-04-01 Cephalon Inc 作為ＡＬＫ及ｃ-ＭＥＴ抑制劑之２，４-二胺基嘧啶之融合雙環衍生物
EP3012249A1 (en) 2006-12-08 2016-04-27 Novartis AG Compounds and composition as protein kinase inhibitors
WO2008076243A2 (en) * 2006-12-14 2008-06-26 Merck & Co., Inc. Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
JP5551689B2 (ja) 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
CN102482277B (zh) * 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CN101935317B (zh) * 2009-07-01 2013-08-28 上海药明康德新药开发有限公司 2-甲基-7-(取代嘧啶-4-氨基)-4-(取代哌啶-1-基)异吲哚啉-1-酮及中间体的合成方法
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) * 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
EP2675794B1 (en) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2975403B1 (en) 2013-02-13 2018-05-02 Hirotomo Shibaguchi Rapid allergy testing method
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
JP2022547719A (ja) * 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニストおよびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6776480B2 (en) 2001-07-18 2004-08-17 Sola International Holdings, Ltd. Spectacle frames for shaped lenses defined by monoformal carrier surfaces
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) * 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2575720C (en) 2012-10-02
CA2575720A1 (en) 2006-03-02
RU2395507C2 (ru) 2010-07-27
NO20071504L (no) 2007-05-25
CN101006079A (zh) 2007-07-25
EP1784399B1 (en) 2011-06-15
EP1784399A2 (en) 2007-05-16
ES2366038T3 (es) 2011-10-14
PT1784399E (pt) 2011-08-26
JP4674236B2 (ja) 2011-04-20
US20080293708A1 (en) 2008-11-27
AU2005276585B2 (en) 2009-07-30
GB0419160D0 (en) 2004-09-29
AR050536A1 (es) 2006-11-01
BRPI0514731A (pt) 2008-06-24
US7910585B2 (en) 2011-03-22
RU2007110946A (ru) 2008-10-10
MA28813B1 (fr) 2007-08-01
JP2008510765A (ja) 2008-04-10
IL181386A0 (en) 2007-07-04
WO2006021457A3 (en) 2006-07-13
WO2006021457A2 (en) 2006-03-02
PL1784399T3 (pl) 2011-11-30
KR20070038567A (ko) 2007-04-10
TW200621728A (en) 2006-07-01
AU2005276585A1 (en) 2006-03-02
KR100894349B1 (ko) 2009-04-22
GT200500229A (es) 2006-03-29
ATE512960T1 (de) 2011-07-15
ECSP077259A (es) 2007-03-29
TNSN07074A1 (en) 2008-06-02

Similar Documents

Publication Publication Date Title
PE20060504A1 (es) Derivados de pirimidina en el tratamiento de cancer
RU2405780C2 (ru) Химические соединения
RS52291B (sr) Ciklični inhibitori proteina tirozin kinaze
PE20171623A1 (es) Agentes inmunomoduladores
CY1118498T1 (el) Παραγωγα πυριδαζινονης
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
PE20040999A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
MA31419B1 (fr) Derives de pyridine
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
NO20071794L (no) Disubstituerte pyrazolobenzodiazepiner nyttige som inhibitorer for CDK2 og angiogenese, og for behandling av bryst, tarm, lunge og prostata cancer
ATE381557T1 (de) Rho-kinase inhibitoren
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
PE20030940A1 (es) Derivados de piridina y pirimidina
GEP20115304B (en) PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
PE20180530A1 (es) Derivados de amidas policiclicas como inhibidores de cdk9
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
MA29926B1 (fr) Derives de pyrazine
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
ECSP10010361A (es) Derivados de piridazinona
PE20060600A1 (es) Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa

Legal Events

Date Code Title Description
FC Refusal